About Virco BVBA and Virco Lab, Inc.
Virco BVBA was established in 1995 by a small, experienced group of scientists and clinicians passionate about and committed to making a difference for patients living with HIV. The primary focus was and remains to discover and develop innovative ways to bring practical and reliable resistance testing tools to healthcare providers, to help them make better informed treatment decisions and to enhance patient care.
As a research-based biotechnology company, we apply the most advanced technologies in molecular biology, virology, genomics, robotics and electronic data processing to improve the diagnosis and management of infectious diseases. Today, we are primarily dedicated to combat HIV and improve the quality of life for patients through the combined application of these technologies.
Acquired by Johnson and Johnson Corporation (New Brunswick, USA) in 2002, Virco BVBA continues to provide value added diagnostic services that enable optimized patient management for infectious diseases.
In addition to supporting patient management in routine clinical care, Virco's unique and extensive knowledge base also supports clinicians, virologists and researchers in pharmaceutical drug development to facilitate the availability of life-enhancing medicines to those in need.
In order to bring our services as widely as possible to market, we work closely with various partner companies and maintain active collaborations with patients and advocates involved in the battle against HIV.
A pioneer in the field of HIV-1 drug resistance testing, our leadership results from translating cutting edge technology into practical diagnostic tools. Virco puts knowledge into practice. Virco invests significant resources in R&D and supports numerous external scientific projects and clinical trials, assuring that our assays incorporate the newest drugs and drug classes and that we remain at the forefront of new developments in HIV resistance and therapy management.
In the US, our HIV drug resistance monitoring services, virco®TYPE HIV-1 and Antivirogram®, are delivered through our US affiliate, Virco Lab, Inc. Our assays are highly advanced, thoroughly researched, subject to stringent quality controls, highly automated and performed in fully accredited laboratories by highly skilled specialist technicians.
For more information about Virco’s products and services please refer to:
Mission Statement
Virco's mission is to provide HIV resistance knowledge to clinicians as they seek to make personalized medical decisions for patients living with HIV/AIDS.
About the LAB TRACKER™ HIV Acquisition
The acquisition of LAB TRACKER™ HIV by Virco BVBA is a natural extension of our mission and seeks to help clinicians make better use of information from multiple sources, including resistance testing information, in order to make individualized patient management decisions.
